ReproCell

ReproCell R&D / Revenue

The R&D to Revenue Ratio of ReproCell (4978.T) as of Oct 30, 2026 is 28.08 %. In the previous year, R&D to Revenue Ratio was 18.02 % — a change of 55.81% (higher).

R&D / Revenue

28.08 %

YoY

55.81%

Last updated:

R&D to Revenue Ratio of ReproCell is 2026 28.08 % . R&D to Revenue Ratio of ReproCell was 2025 18.02 % . It decreases by 55.81% higher compared to the previous year.

The ReproCell R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2019
25.10 JPY
Jan 1, 2020
37.90 JPY
Jan 1, 2021
51.47 JPY
Jan 1, 2022
23.95 JPY
Jan 1, 2023
16.98 JPY
Jan 1, 2024
15.86 JPY
Jan 1, 2025
18.02 JPY
Jan 1, 2026
28.08 JPY
The ReproCell R&D / Revenue history
YEARR&D / RevenueYoY
28.08 %+55.81%
18.02 %+13.61%
15.86 %-6.59%
16.98 %-29.11%
23.95 %-53.46%
51.47 %+35.80%
37.90 %+50.99%
25.10 %+21.32%
20.69 %-5.87%
21.98 %-19.00%
27.13 %-45.09%
49.41 %+89.68%
26.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

R&D to Revenue Ratio of ReproCell is 28.08 % in 2026.

R&D to Revenue Ratio of ReproCell changed from 18.02 % to 28.08 %, representing a 55.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio ReproCell since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's ReproCell with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — ReproCell

All Key Metrics — ReproCell